2 pharma firms to mine gene data from 500,000 Britons
London
BRITAIN'S GlaxoSmithKline and US-based Regeneron Pharmaceuticals are embarking on a joint project with UK Biobank, the world's most detailed biomedical database, to hunt for new clues linking genes and disease.
By analysing genetic variations and health in 500,000 middle-aged and older Britons, the partners said on Thursday that they hoped to identify promising leads for new medicines.
The aim is to analyse DNA from an initial 50,000 samples by the end of 2017, using Regeneron's large gene sequencing centre in New York. Completing a gene sweep for all 500,000 participants is expected to take three to five years. The move marks an acceleration of investment by drugmakers in genetic science, as industrial-scale sequencing and falling co…
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action
France's Casino supermarket chain to axe up to 3,200 jobs
Prada outshines rivals with 16% revenue lift boosted by Miu Miu
Toymaker Hasbro posts quarterly profit beat, slower sales decline